ABCL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AbCellera Biologics Inc (ABCL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The recent collaboration with Jazz Pharmaceuticals, which includes substantial upfront and milestone payments, provides a strong positive catalyst for future growth. While technical indicators are neutral, the stock's price is relatively low, and analysts maintain a positive outlook with increased price targets. The options data also reflects bullish sentiment, suggesting potential upside.
The MACD histogram is negative (-0.0791) but contracting, indicating weakening bearish momentum. RSI is neutral at 56.682, and moving averages are converging, suggesting no clear trend. Key support is at 5.051, and resistance is at 6.06. The stock is trading near its pivot level of 5.555.
The $848 million collaboration with Jazz Pharmaceuticals is a significant positive catalyst, providing both immediate and long-term financial benefits. Analysts have raised price targets, and the company's antibody discovery platform has been validated through multiple clinical advancements.
Technical indicators are neutral, and there is no recent congress trading data or insider buying activity to further support bullish sentiment.
Financial data is unavailable for the latest quarter, but the recent partnership with Jazz Pharmaceuticals indicates strong potential for future revenue growth.
Analysts are bullish on the stock. Stifel raised the price target to $8 from $7, maintaining a Buy rating. Cantor Fitzgerald initiated coverage with an Overweight rating and a $7 price target. JonesResearch initiated coverage with a Buy rating and an $11 price target, citing the company's validated antibody discovery platform and collaborations with major players like Eli Lilly.
